AUROBINDO

PRESS RELEASE

1st June 2011

Aurobindo Pharma receives final approval for Donepezil Hydrochloride Tablets from USFDA

Aurobindo Pharma Limited is pleased to announce that its tentatively approved ANDA for Donepezil Hydrochloride Tablets 5mg and 10mg (ANDA No. 090056) has received the final approval from the US Food & Drug Administration (USFDA).

Donepezil Hydrochloride Tablets 5mg and 10mg is the generic equivalent to Aricept® Tablets 5mg and 10mg of Eisai Medical Research Inc. Donepezil Hydrochloride Tablets are indicated for the treatment of mild, moderate, and severe dementia of the Alzheimer's type and fall under the Central Nervous System (CNS) therapeutic segment. The product has a market size of approximately US$ 2.5 billion for the twelve months ending September 2010 according to IMS and will be launched soon.

Aurobindo now has a total of 136 ANDA approvals (106 Final approvals and 30 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:
Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com